CMOP±R for untreated non-Hodgkin's lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of chemotherapy drugs (CMOP with or without R) for people with newly diagnosed non-Hodgkin's lymphoma who have not received treatment yet. It aims to see how well the treatment works and if it is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been newly diagnosed with non-Hodgkin's lymphoma and have not had treatment yet.
- You have at least one tumor that can be measured on a scan (lymph node larger than 1.5 cm or other lesion larger than 1 cm).
- You are generally able to take care of yourself (ECOG score 0-2).
- Your blood counts and liver/kidney function are within acceptable ranges.
- You do not have serious heart problems, active hepatitis B or C, HIV, or other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (HSK47977) to see how it works in people with non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to understand how the drug is processed by the body, its safety, and whether it can help shrink tumors.
This trial tests two different drug combinations to see which is better for people with a type of lymphoma that has certain genetic markers. It aims to improve outcomes for patients who have not received treatment before.
This trial tests a new drug called XNW5004 combined with standard chemotherapy for people who have just been diagnosed with peripheral T-cell lymphoma and haven't had treatment yet. The goal is to see if adding XNW5004 helps more than chemotherapy alone.
This trial tests a combination of chemotherapy and a targeted drug (zanubrutinib) for people with a type of lymphoma (DLBCL) that has spread to the brain or spinal fluid. The goal is to see if this treatment can better control the disease and improve outcomes.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
This trial tests if a new treatment called RGL-305 can help people with lymphoma who still have tiny amounts of cancer cells left after previous treatment. It is for those whose disease has responded to prior therapy but is not completely gone at the genetic level.
Hear when a new NHL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.